Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s... | May 4, 2023